Table 3.
Therapeutic outcomes of the PTC-with-HPT group and control group.
| Outcome | Number of events (%) |
PTC-with-HPT vs. control |
||
|---|---|---|---|---|
| PTC-with-HPT | Control | HR (95% CI) | p-value | |
| Residual disease | 1 (3.8) | 4 (3.9) | 0.96 (0.11–8.60) | 0.97 |
| Recurrent disease | 2 (7.7) | 3 (2.9) | 2.59 (0.43–15.50) | 0.30 |
| Disease non-remission | 3 (11.5) | 7 (6.8) | 1.66 (0.43–6.40) | 0.47 |
| Thyroid cancer related mortality | 0 | 1 (1.0) | NA | NA |
| Non-thyroid cancer related mortality | 4 (15.4) | 3 (2.9) | 5.93 (1.32–26.52) | 0.02a |
| Overall mortality | 4 (15.4) | 4 (3.9) | 4.43 (1.11–17.75) | 0.04a |
| Composite outcome | 7 (26.9) | 10 (9.7) | 2.79 (1.06–7.33) | 0.04a |
Abbreviations: HR: hazard ratio; CI: confidence interval; NA: not applicable.
a
Statistical significance.